Signal Cards
8Source-context cards packaged for review.
Sample report
Daily Signal Card report.
This email is the human-readable report customers receive for watchlist matches. It packages public FDA/openFDA watchlist matches with source links for internal review.
This browser page mirrors the customer-readable output so teams can inspect the report format before subscribing.
Sample generated from the April 26, 2026 public-source run. This is public-data monitoring only, not clinical, purchasing, sourcing, procurement, inventory, substitution, dispensing, or emergency advice.
Current records
1,147Public records marked Current in the sample pull.
Detected changes
0No row-level changes since the previous snapshot.
How to read this
FDA status is the status in the public shortage record. Why this appeared explains the watchlist or sample match path. Context sources found counts public source layers with usable context for verification.
Related public records and listed companies describe matching public records. They are not inventory or procurement recommendations.
Signal Card
Carboplatin Injection
FDA statusCurrent
Why this appearedPublic-source sample record
Context sources found4 source layers
Public-record change: Current public shortage record included for source context.
Related public records: 29. Listed companies: 8. Latest public update: April 24, 2026.
Core FDA/openFDA record
The public shortage record that triggered this Signal Card. Use these links to verify against FDA/openFDA.
NDC product context
1 product; 1 package; labeler BPI Labs LLC; form INJECTION, SOLUTION; route INTRAVENOUS.
RxNorm name matching
Paraplatin, Kyxata, carboplatin.
DailyMed label links
1 related public label link.
ASHP/UUDIS handling
External index link only. Bulletin content is not copied, summarized, rewritten, or used for synthesized reporting.
Signal Card
Dexamethasone Sodium Phosphate Injection
FDA statusCurrent
Why this appearedPublic-source sample record
Context sources found4 source layers
Public-record change: Current public shortage record included for source context.
Related public records: 16. Listed companies: 5. Latest public update: April 23, 2026.
Core FDA/openFDA record
Source-linked public shortage record with openFDA query path for verification.
NDC product context
1 product; 1 package; labeler Fresenius Kabi USA, LLC; form INJECTION, SOLUTION; routes INTRAMUSCULAR, INTRAVENOUS.
RxNorm name matching
dexamethasone, dexamethasone sodium phosphate.
Signal Card
Lidocaine Hydrochloride Injection
FDA statusCurrent
Why this appearedPublic-source sample record
Context sources found4 source layers
Public-record change: Current public shortage record included for source context.
Related public records: 70. Listed companies: 10. Latest public update: April 23, 2026.
Core FDA/openFDA record
Source-linked public shortage record with openFDA query path for verification.
NDC product context
1 product; 4 packages; labeler Fresenius Kabi USA, LLC; form INJECTION, SOLUTION; routes EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL.
RxNorm name matching
Ana-Lex, Regenecare, Cutiecaine, Burn Jel Plus, ProCoMycin.
Boundaries
FormularySignal monitors public records and source context for verification. It does not provide medical advice, prescribing advice, substitution guidance, inventory recommendations, procurement recommendations, patient-specific workflows, causality claims, or FDA endorsement.